Nuvalent, Inc.

Please be aware of fraudulent job postings and individuals falsely claiming to be employees of Nuvalent. These scams often request sensitive personal or financial information. ✅ Legitimate Nuvalent emails come only from @nuvalent.com ✅ System response emails from our Greenhouse applicant tracking system come from a no-reply@greenhouse.io email address ✅ All job offers follow a formal application + interview process ❌ We never request personal/financial info via email If you’ve been contacted by someone misrepresenting Nuvalent, please report it to jobfraud@nuvalent.com and/or 857-357-7000. Thank you for staying vigilant!

We’re heading to sunny San Diego as a proud sponsor of this year’s ALK Positive Inc. Summit! We look forward to connecting with patients, caregivers, and healthcare experts as we explore the latest in #ALK+ NSCLC research and cancer care. Register to join virtually: https://lnkd.in/ghqZTsQj #StrongerTogether #ALKSummit25 #LungCancer

🎉Milestone Alert: The #NuCrew is 200 strong! 🚀 From our first hire to our 200th team member, we’re grateful for the collaboration, passion, and talent that every individual brings to Nuvalent. To our incredible team, thank you for your belief in our mission. You've helped shape who we are today: a passionate, patient-focused, and purpose-driven organization. We’re excited for all we’ll continue to achieve together.

Driven by purpose and fueled by collaboration (and good food!), the #NuCrew is united by our shared goal of making a meaningful difference for patients. Check out our latest roles in Clinical, Quality, Pharmaceutical Development, and more: https://lnkd.in/g2yuEE8M #careers #biotech

We’re proud to support the DAVA Oncology 4th Summit on Thoracic Malignancies, which brings together global experts in #LungCancer research and care. We look forward to engaging discussions, expert insights, and new approaches shaping the future of thoracic oncology.

Last week, some of our #NuCrew colleagues swapped their office chairs for running shoes and hit the pavement at the Boston J.P. Morgan Corporate Challenge! From walkers to runners, first-timers to seasoned athletes, our team showed up with energy, camaraderie, and a shared commitment to wellness.

Today, we shared positive topline results for zidesamtinib in TKI pre-treated patients with advanced ROS1+ NSCLC from our global Phase 1/2 ARROS-1 clinical trial.    This pivotal dataset is more than just a milestone — it's a reflection of the patients and purpose that drive us, and a meaningful step toward our goal of making a positive impact on the lives of people with cancer.    To the ROS1+ community, your journey motivates everything we do, and we're committed to walking alongside you in pursuit of better outcomes. Learn more here: https://lnkd.in/erki2BSH

⚡ TUNE IN TOMORROW: Pivotal data for TKI pre-treated patients with advanced ROS1+ NSCLC from our ARROS-1 clinical trial of zidesamtinib is coming. Join our live webcast & conference call on June 24, 2025 at 8:00am ET. Learn more: https://lnkd.in/ewi7hHFC

Please join us in giving a warm welcome to our newest #NuCrew members, Aria, Denise, Misha, Molly, and Drew. We’re thrilled to have such passionate, curious, and purpose-driven individuals joining us in our mission to make a real difference for patients.

We’re pleased to welcome Christy Oliger to our board of directors! Christy’s proven success in delivering new therapies to patients living with cancer adds valuable perspective to our team as we prepare for a potential first approval in 2026 from our pipeline of #PreciselyTargetedTherapies. Learn more: https://lnkd.in/daScFVfN